CytomX Therapeutics to Announce First Quarter 2020 Financial Results
27 Abril 2020 - 7:00AM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational antibody therapeutics based on its Probody®
therapeutic technology platform, plans to report first quarter 2020
financial results on Thursday, May 7, 2020, after the close of U.S.
markets. Following the announcement, the company will host a
conference call beginning at 5:00 p.m. ET to discuss its results.
Participants may access the live audio webcast of the
teleconference from the “Investors & News” section of CytomX’s
website at http://ir.cytomx.com/. Please access the website 15
minutes prior to the start of the call to download and install any
necessary audio software.
Audio Conference Call:
U.S. Dial-in Number: |
(877) 809-6037 |
|
|
International Dial-in Number: |
(615)
247-0221 |
|
|
Conference ID: |
6282129 |
An archived webcast replay will be available on the Company's
website from May 7, 2020, until May 14, 2020.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical
company with a vision of transforming lives with safer, more
effective therapies. We are developing a novel class of
investigational antibody therapeutics, based on our
Probody® technology platform, for the treatment of cancer.
Probody therapeutics are designed to remain inactive until they
are activated by proteases in the tumor microenvironment. As a
result, Probody therapeutics are intended to bind selectively to
tumors and decrease binding to healthy tissue, to minimize toxicity
and potentially create safer, more effective therapies. As leaders
in the field, our innovative technology is designed to turn
previously undruggable targets into druggable targets and to enable
more effective combination therapies. CytomX and its partners,
comprised of leading biotechnology and pharmaceutical companies,
have developed a robust pipeline of potential first-in-class
therapeutic candidates against novel, difficult to drug targets and
potential best-in-class immunotherapeutic candidates against
clinically validated targets. The CytomX clinical stage pipeline
includes first-in-class product candidates against previously
undruggable targets, including a CD166-targeting Probody drug
conjugate wholly owned by CytomX (CX-2009) and a CD71-targeting
Probody drug conjugate partnered with AbbVie (CX-2029). CD166 and
CD71 are among cancer targets that are considered to be
inaccessible to conventional antibody drug conjugates due to their
presence on many healthy tissues. The CytomX clinical stage
pipeline also includes cancer immunotherapeutic candidates against
validated targets such as the CTLA-4-targeting Probody
therapeutics, BMS-986249 and BMS-986288, partnered with Bristol
Myers Squibb. CytomX has strategic drug discovery and development
collaborations with AbbVie, Amgen, Astellas and Bristol Myers
Squibb. For additional information about CytomX Therapeutics,
visit www.cytomx.com and follow us
on LinkedIn and Twitter.
Probody is a U.S. registered trademark of CytomX
Therapeutics, Inc.
Investor and Media Contact:
Christopher Keenan VP, Investor Relations and Corporate
Communications ckeenan@cytomx.com
650-383-0823
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024